Q-omics provides the consensus-scored PRDX2P3 profile across patient tissues and cancer cell-line models. PRDX2P3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PRDX2P3 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, PRDX2P3 RNA expression shows 15,911 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where PRDX2P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDX2P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDX2P3 survival associations across molecular data types. PRDX2P3 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDX2P3 RNA expression–survival associations across cancer types. High PRDX2P3 expression shows unfavorable associations in UVM, ACC, PCPG and SKCM, but favorable associations in UCEC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for PRDX2P3 RNA expression.
This table summarizes PRDX2P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PRDX2P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDX2P3 shows lower tumor expression in LUSC, KICH and THCA and higher tumor expression in HNSC, CHOL and KIRC. The HNSC box plot shows higher PRDX2P3 RNA expression in tumor versus normal tissue (log2 FC = +0.063, t-test p = .002).
This table shows molecular features associated with PRDX2P3 in patient tissues and cancer cell lines. In patient samples, PRDX2P3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
